Tuesday, July 23, 2019 Daily Archives

VGXI to supply plasmid for Geneos’ cancer DNA vaccines

by

Plasmid manufacturer VGXI has entered a long-term supply agreement to support development of Geneos Therapeutics’ personalized cancer vaccines. “DNA vaccines are unique from typical vaccines in that they contain no protein components,†Christy Franco, senior manager of BD at VGXI, told this publication. “A synthetic, circular DNA encodes for portions of the patient’s tumor that have been identified as immunogenic. After delivery, the DNA vaccine expresses those protein segments which trigger your body’s immune system to identify, track down, and…

July 23, 2019

Avalon GE partnership looks to automate and accelerate CAR-Ts

by

Avalon GloboCare has teamed with GE Healthcare to establish automated and standardized cell production capabilities to support its cellular immunotherapy programs. Under terms of the deal, clinical stage biotech Avalon will access bioprocess vendor GE Healthcare’s FlexFactory Cell Therapy platform to develop a production infrastructure for its pipeline of Chimeric Antigen Receptor (CAR) T cells and other immune-effector cells for cellular immunotherapy. Avalon will also gain access to GE’s FastTrak process development and training services, as well as its extensive…

July 23, 2019

‘Bioprocessing ecosystem is on fire,’ says analyst

by

Sales grew 21% year-on-year at Sartorius’ H1 2019, while Repligen reported preliminary Q2 growth of nearly 50%. The bioprocessing sector ‘is on fire,’ says Jefferies’ analyst Brandon Couillard. Repligen Corporation published its preliminary Q2 results in an SEC filing last week, saying it expects sales of $70-71 million, compared to $47.7 million for the three months ended June 30, 2018. This would represent a 48% increase year-on-year. “The 8-K did not offer much color on specific drivers, but momentum across…

July 23, 2019